drugset / Trial / NCT03009877

Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask

NCT03009877

RandomizedParallel-groupOpen-labelTreatment

Summary

Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. This study will examine whether Optiflow can do this, and compare the pre-oxygenation with Optiflow to the pre-oxygenation achieved with face mask.

Timeline

Start
2018-07
Primary completion
2019-05
Completion
2019-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Fentanyl Other / unclassified 2 ug/kg
Background Midazolam Small molecule 1 mg
Background Midazolam Small molecule 2 mg
Background Propofol Small molecule 50 ug
Background Propofol Small molecule 150 ug
Background Rocuronium Other / unclassified 0.6 mg/kg

Indications